lidoflazine has been researched along with Reperfusion Injury in 2 studies
Lidoflazine: Coronary vasodilator with some antiarrhythmic action.
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobsson, J | 2 |
| Sundberg, R | 1 |
| Rilo, HL | 1 |
| Gasbarrini, A | 1 |
| Starzl, TE | 1 |
| Van Thiel, D | 1 |
| Odlind, B | 1 |
| Tufveson, G | 1 |
| Wahlberg, J | 1 |
2 other studies available for lidoflazine and Reperfusion Injury
| Article | Year |
|---|---|
Protective effects of the lazaroid U74500A and lidoflazine on liver preservation with UW solution.
Topics: Adenosine; Alanine Transaminase; Allopurinol; Animals; Aspartate Aminotransferases; Glutathione; Ins | 1993 |
Improvement of renal preservation by adding lidoflazine to University of Wisconsin solution. An experimental study in the rat.
Topics: Adenosine; Allopurinol; Animals; Cold Temperature; Erythrocytes; Glutathione; Insulin; Kidney; Kidne | 1992 |